Herrmann R - Search Results

1

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C. Wicki A, et al. Among authors: herrmann r. Clin Cancer Res. 2012 Jan 15;18(2):454-64. doi: 10.1158/1078-0432.CCR-11-1102. Epub 2011 Nov 7. Clin Cancer Res. 2012. PMID: 22065082

2

EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.

Mamot C, Ritschard R, Küng W, Park JW, Herrmann R, Rochlitz CF. Mamot C, et al. Among authors: herrmann r. J Drug Target. 2006 May;14(4):215-23. doi: 10.1080/10611860600691049. J Drug Target. 2006. PMID: 16777680

3

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C. Mamot C, et al. Among authors: herrmann r. J Drug Target. 2012 Jun;20(5):422-32. doi: 10.3109/1061186X.2012.680960. Epub 2012 Apr 23. J Drug Target. 2012. PMID: 22519893

4

Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer.

Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C. Buess M, et al. Among authors: herrmann r. Neoplasia. 2009 Oct;11(10):987-1002. doi: 10.1593/neo.09670. Neoplasia. 2009. PMID: 19794958 Free PMC article.

5

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C. Mamot C, et al. Among authors: herrmann r. Lancet Oncol. 2012 Dec;13(12):1234-41. doi: 10.1016/S1470-2045(12)70476-X. Epub 2012 Nov 13. Lancet Oncol. 2012. PMID: 23153506 Clinical Trial.

6

Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study.

Wicki A, Hermann F, Prêtre V, Winterhalder R, Kueng M, von Moos R, Rochlitz C, Herrmann R. Wicki A, et al. Among authors: herrmann r. Oncol Res Treat. 2014;37(5):230-6. doi: 10.1159/000362376. Epub 2014 Apr 8. Oncol Res Treat. 2014. PMID: 24853781 Clinical Trial.

7

A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.

Salzberg M, Pless M, Rochlitz C, Ambrus K, Scigalla P, Herrmann R. Salzberg M, et al. Among authors: herrmann r. Invest New Drugs. 2006 Jul;24(4):299-304. doi: 10.1007/s10637-005-4061-z. Invest New Drugs. 2006. PMID: 16237511 Clinical Trial.

8

IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients.

Rajski M, Zanetti-Dällenbach R, Vogel B, Herrmann R, Rochlitz C, Buess M. Rajski M, et al. Among authors: herrmann r. BMC Med. 2010 Jan 5;8:1. doi: 10.1186/1741-7015-8-1. BMC Med. 2010. PMID: 20051100 Free PMC article.

9

[Possibilities and prospects in gene therapy in cancer patients].

Rochlitz CF, Herrmann R. Rochlitz CF, et al. Among authors: herrmann r. Ther Umsch. 1996 Nov;53(11):847-53. Ther Umsch. 1996. PMID: 8984690 Review. German.

10

Cancer gene and immunotherapy: recent developments.

Jantscheff P, Herrmann R, Rochlitz C. Jantscheff P, et al. Among authors: herrmann r. Med Oncol. 1999 Jul;16(2):78-85. doi: 10.1007/BF02785840. Med Oncol. 1999. PMID: 10456655 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,049 results

Search Page

Filters